EGFR and neoplasm: In this study, we evaluated the ability of ZD4190, an orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, to block the development of vasculature required to support outgrowth of tumour cells (Wedge et al, 2000; Ryan and Wedge, 2005).